CLC bio establishes independent non-profit foundation to give back to the genomics community
Chairman of the Genomics Enlightenment Foundation and CEO of CLC bio, Thomas Knudsen, states, "Instead of sponsoring multiple small non-profit events, we have decided to focus all our sponsoring efforts by establishing and funding an independent foundation, with the aim of facilitating events that will present cutting-edge research within high-throughput sequencing and genomics analyses. This is CLC bio's way of giving back to the genomics community through the independently run Genomics Enlightenment Foundation."
Boardmember of the Genomics Enlightenment Foundation and Professor at the Department of Molecular Medicine at Aarhus University Hospital, Dr. Torben Ørntoft, adds, "The aim of Copenhagenomics is to share global best-practice on utilizing the latest DNA sequencing technologies for research into improving human health. Some of the research areas that will be represented are cancer genomics, NGS-based molecular diagnostics, population genomics, metagenomics, and nutrigenomics. Our goal is not to make this a big commecial event - we rather want to limit the attendance to around 200 people and focus on high quality talks."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.